FierceBiotechIT writer Ryan McBride reports that GlaxoSmithKline (GSK) launched a website that will allow authorized researchers the ability to use clinical study data on certain drugs from the London based pharma company. This launches GSK to the forefront of...
Numerous pharmaceuticals are approved and marketed based on the premise that they favorably change disease state-biomarkers. However, recent data has shown that altering the biomarkers indicative of disease does not necessarily translate to ameliorated health. In an...
One of the greatest challenges of clinical research is patient recruitment and retention according to Tufts Center for the Study of Drug Development (CSDD). To help clinical research professionals improve clinical trial management, Tufts CSDD analyzed more than 150...
The Tufts Center for the Study of Drug Development (CSDD) published its Outlook 2013 report on pharmaceutical trends. Although Tufts CSDD Director Kenneth I Kaitlin is optimistic about the future of dug innovation, he believes companies needs to identify and reduce...
The Presidential Commission for the Study of Bioethical Issues, a government advisory panel, released a statement reinforcing the need for privacy protection for those who choose to submit their whole genome sequencing for the purpose of medical research. Genomes...
FierceBiotech has compiled a list of the 20 top pharma-academic collaborations from 2012 which can be found here. This list notes the Big Pharma players who have collaborated with universities and academic medical centers and gone above and beyond typical research...
